BSE · 524790
Everest Organics Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹160 Cr with net profit ₹-1 Cr — a -0.81% net margin, versus 0.07% the period before.
Shareholding
As of 2026-06-30
- Promoter59.6%
- Public40.37%
- DII0.02%
7,827 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.72× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #11 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,05,990 Cr | 274.09 | 12.27 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,117 Cr | 205.85 | 16.4 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,730 Cr | 116.28 | 13.26 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,570 Cr | 129.47 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,731 Cr | 67.56 | 2.41 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,709 Cr | 110.63 | 4.72 | 12.98% | 11.5% |
| Hikal Limited | ₹2,719 Cr | 188.46 | 2.27 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,248 Cr | 248.38 | 9.19 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,000 Cr | 148.28 | 6.08 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,319 Cr | 67.27 | 3.16 | 17.67% | 13.66% |
| Everest Organics Ltd.(this company) | ₹300 Cr | 54.01 | 3.77 | 7.35% | 2.83% |
AI analysis
AI-generated · google/gemini-2.5-flashEverest Organics Ltd. is listed on the Indian markets with a market capitalization of Rs 322 Cr. The company reported a revenue of Rs 160.17 Cr and a profit margin of 283.5% in the last fiscal.
Positives
- +The promoter holding is 59.603% as of June 30, 2026.
- +The company has no promoter share pledges reported.
- +The debt-to-equity ratio is 0.91, indicating a moderate level of debt.
Negatives
- −Revenue decreased from Rs 198.1274 Cr in Mar 2024 to Rs 160.1659 Cr in Mar 2025.
- −The company reported a net loss of Rs 1.2903 Cr in Mar 2025.
- −Return on equity (ROE) of 7.35% is relatively low.
- −The company had negative EPS of -2.97 in Mar 2025.
Financial Performance
Everest Organics Ltd.'s annual revenue has fluctuated over recent years, reaching Rs 160.1659 Cr in Mar 2025 from Rs 182.6286 Cr in Mar 2021. Net profit also varied, reporting a loss of Rs 1.2903 Cr in Mar 2025, compared to a profit of Rs 13.715 Cr in Mar 2021. Quarterly revenue in Mar 2026 was Rs 48.75 Cr, with a net profit of Rs 2.63 Cr.
Profitability & Returns
The company's profitability, as indicated by return on equity (ROE), stood at 7.35%. Return on capital employed (ROCE) was 11.6212%. The reported profit margin was 283.5%. Earnings per share (EPS) for the last fiscal year was 5.56.
Balance Sheet
Everest Organics Ltd. has a debt-to-equity ratio of 0.91. The book value per share is Rs 79.69.
Ownership & Pledges
There were no promoter shares pledged.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.